Ayala Pharmaceuticals, Inc.
BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS FOR TREATING NOTCH-ACTIVATED BREAST CANCER

Last updated:

Abstract:

The present invention provides methods of reducing tumor size, suppressing or inhibiting tumor growth, or prolonging progression-free survival or overall survival in subjects having Notch-activated breast cancer by administering compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds, including compounds of Formula (III): or prodrugs thereof, alone or in combination with a composition comprising a cytotoxic agent. Notch-activated breast cancer may be determined by a) Notch-activating genetic alterations in one or more Notch genes, b) overexpression of one or more Notch-regulated genes, c) overexpression of one or more Notch proteins or Notch-regulated proteins, or a combination thereof. ##STR00001##

Status:
Application
Type:

Utility

Filling date:

14 May 2020

Issue date:

4 Aug 2022